High-Dose-Rate Brachytherapy for Primary Treatment of Refractory Proliferative Verrucous Leukoplakia of the Hard Palate.

brachytherapy oral cavity cancer oral leukoplakia proliferative verrucous leukoplakia radiotherapy

Journal

Cureus
ISSN: 2168-8184
Titre abrégé: Cureus
Pays: United States
ID NLM: 101596737

Informations de publication

Date de publication:
Jun 2021
Historique:
accepted: 16 06 2021
entrez: 19 7 2021
pubmed: 20 7 2021
medline: 20 7 2021
Statut: epublish

Résumé

Oral proliferative verrucous leukoplakia (PVL) is a rare, progressive form of leukoplakia with a high rate of malignant transformation. No therapies are known to lower the rate of malignant transformation and prevent a recurrence. An 84-year-old patient with a years-long history of symptomatic PVL of the hard palate refractory to CO2 laser ablation presented to the radiation oncology clinic for consideration of non-surgical management. High dose rate brachytherapy was used to deliver 36 Gy in 12 fractions to the hard palate using an Ir-192 source with a custom-molded applicator. By three months of follow-up, the patient had complete regression of the PVL and resolution of acute mucositis. With 18 months of follow-up, the patient remains disease- and symptom-free without toxicities of treatment. High dose rate surface applicator brachytherapy is a feasible and potentially effective treatment for oral PVL, yielding durable control with low long-term toxicity.

Identifiants

pubmed: 34277283
doi: 10.7759/cureus.15696
pmc: PMC8285093
doi:

Types de publication

Case Reports

Langues

eng

Pagination

e15696

Informations de copyright

Copyright © 2021, Mohiuddin et al.

Déclaration de conflit d'intérêts

The authors have declared that no competing interests exist.

Références

Int J Radiat Oncol Biol Phys. 2001 Aug 1;50(5):1190-8
pubmed: 11483328
Radiother Oncol. 1996 Apr;39(1):15-8
pubmed: 8735489
Oral Surg Oral Med Oral Pathol. 1985 Sep;60(3):285-98
pubmed: 3862042
Oral Oncol. 2004 Sep;40(8):835-40
pubmed: 15288840
Int J Radiat Oncol Biol Phys. 1996 Dec 1;36(5):1201-4
pubmed: 8985043
Braz J Otorhinolaryngol. 2017 Sep - Oct;83(5):585-593
pubmed: 28209441
Pract Radiat Oncol. 2015 Mar-Apr;5(2):74-8
pubmed: 25413412
Radiother Oncol. 2018 Mar;126(3):377-385
pubmed: 29455924
Radiat Oncol. 2015 Apr 08;10:81
pubmed: 25888772
Head Neck. 2017 Oct;39(10):1997-2003
pubmed: 28640498
Strahlenther Onkol. 2013 Oct;189(10):894-8
pubmed: 23963206
Head Neck. 2020 Mar;42(3):539-555
pubmed: 31803979
Laryngoscope. 1999 Dec;109(12):1967-73
pubmed: 10591356

Auteurs

Jahan J Mohiuddin (JJ)

Radiation Oncology, University of Pennsylvania, Philadelphia, USA.

Rabie M Shanti (RM)

Otolaryngology - Head and Neck Surgery, University of Pennsylvania, Philadelphia, USA.

Faizan Alawi (F)

Dermatopathology, Division of Oral and Maxillofacial Pathology, University of Pennsylvania, Philadelphia, USA.

Brian M Chang (BM)

Oral and Maxillofacial Surgery, University of Pennsylvania, Philadelphia, USA.

Jaclyn Marcel (J)

Radiation Oncology, University of Pennsylvania, Philadelphia, USA.

Neil K Taunk (NK)

Radiation Oncology, University of Pennsylvania, Philadelphia, USA.

John N Lukens (JN)

Radiation Oncology, University of Pennsylvania, Philadelphia, USA.

Classifications MeSH